Utah Study Tests Transcranial Magnetic Stimulation for Perinatal Depression
A prospective study in Salt Lake City is taking a close look at transcranial magnetic stimulation for women living with perinatal depression, a population in which treatment decisions often involve balancing symptom control against concerns about medication exposure during pregnancy or early motherhood. The open-label trial is designed to determine whether TMS can be delivered feasibly, accepted by participants, and tolerated safely across pregnancy and the first postpartum year.
The protocol is straightforward and clinically ambitious. Up to 100 women age 22 years and older will enroll if they are pregnant between 12 and 28 weeks or are within 12 months after delivery, meet DSM-5 criteria for a major depressive episode, and have an Edinburgh Postnatal Depression Scale score of at least 13. Every participant receives active TMS; there is no placebo arm, no sham stimulation, and no comparator group. In practical terms, this is a real-world feasibility study, not a definitive efficacy trial.
One sentence captures the central question: can a demanding neuromodulation schedule be carried out safely and consistently in this vulnerable period of life?
Why a Nonpharmacologic Option Matters in Pregnancy and Postpartum Care
Depression during pregnancy and after childbirth carries substantial maternal and infant risk. Symptoms can impair sleep, appetite, bonding, daily functioning, and the ability to engage in prenatal or postpartum care. Severe or persistent depression also raises concern for broader obstetric and neonatal consequences, making treatment essential rather than optional.
TMS has a biologically plausible role in this setting because it uses magnetic pulses applied to the scalp to modulate cortical circuits involved in mood regulation. The protocol targets the left dorsolateral prefrontal cortex, a region long associated with depressive symptom control and affective regulation. By influencing activity in that network, TMS may reduce depressive symptoms without introducing systemic drug exposure, a feature that can matter to patients who prefer to avoid pharmacologic treatment or who have not responded fully to medication.
The study reflects that clinical logic directly. It is not trying to solve every question at once. Instead, it asks whether TMS can be delivered in a perinatal population with enough consistency, satisfaction, and safety to justify a larger controlled trial later.
Daily Treatment Burden and What the Trial Will Measure
Participants will receive an individualized course of stimulation using established clinical parameters. Treatment will last at least 20 sessions, with additional sessions allowed as needed up to a maximum of 36 sessions. The schedule is intensive: up to five sessions per week over roughly 4 to 8 weeks. For a pregnant patient managing work, childcare, transportation, and prenatal appointments, that burden is not trivial. For a postpartum patient recovering physically and caring for an infant, the logistics are equally demanding.
Feasibility will be judged by retention and adherence, including the proportion of participants who complete at least 20 sessions and the proportion who attend at least 80% of scheduled visits. Acceptability will be evaluated through participant-reported satisfaction. Safety monitoring will include adverse events, maternal outcomes, fetal outcomes when applicable, and the completeness of clinical data. Those endpoints are appropriate for a first step because a treatment can only move forward in this setting if patients can actually complete it and if obstetric oversight remains manageable.
The investigators will also track depressive symptoms, anxiety, rumination, sleep quality, trauma-related symptoms, daily functioning, and maternal attachment. Weekly assessments during treatment and a follow-up visit about one month after the last session will help determine whether any early symptom gains persist beyond the acute stimulation period. Response and remission rates will be explored, but the single-arm design means these measures will remain preliminary rather than comparative.
Pregnancy and Infant Follow-Up Extends the Safety Lens
For women enrolled during pregnancy, the study adds a six-month review of maternal and infant medical records after delivery. That element broadens the safety assessment beyond the treatment window itself. It includes pregnancy and delivery complications, postpartum health, birth characteristics, neonatal complications, and infant health through six months of age.
This follow-up is clinically important because perinatal interventions should be judged not only by immediate tolerability but also by downstream maternal and neonatal outcomes. A therapy that looks acceptable in the short term but disrupts obstetric care or raises concerns after birth would not be especially useful in practice. The added record review gives the protocol a stronger safety frame than a brief symptom-only study would offer.
No comparison group is built into the design, so any improvement in depressive symptoms will have to be interpreted cautiously. Still, open-label data can answer an important question that often precedes randomized testing: can the intervention be delivered in the population that needs it?
Eligibility Criteria Reflect a Careful Safety Boundary
The study limits enrollment to women who can provide informed consent and complete all procedures. It excludes individuals with metal implants or other contraindications to TMS, with the exception of TMS- and MRI-safe dental implants. It also excludes lifetime diagnoses of schizophrenia, bipolar disorder, schizoaffective disorder, autism spectrum disorder, obsessive-compulsive disorder, or psychosis.
Active suicidal or homicidal ideation excludes participation, as do active substance use disorders other than nicotine use disorder. The protocol also excludes people taking medications that, in the principal investigator’s judgment, significantly lower seizure threshold, as well as those with a personal history of seizures, epilepsy, or a first-degree family history of epilepsy or seizures. Those criteria matter because TMS remains a neuromodulation procedure with seizure risk considerations, even though the treatment is noninvasive and already cleared by the U.S. Food and Drug Administration for major depressive disorder in adults.
The result is a focused clinical sample. It is not meant to represent every patient with postpartum mood symptoms. It is designed to test feasibility under carefully controlled conditions in women with a documented major depressive episode and a clinically meaningful symptom burden.
What This Trial Can and Cannot Tell Clinicians
The study started on September 23, 2026, is listed as active but not recruiting, and is expected to complete primary analysis in September 2028 with final study completion projected for May 2029. Those dates place the work squarely in the early evidence-building phase.
Because all participants receive TMS, the trial cannot determine whether the intervention outperforms usual care, sham stimulation, psychotherapy, or medication. It also cannot isolate which symptom domains improve most robustly or how much of any observed change is due to the treatment versus the natural course of perinatal mood symptoms. What it can do is establish whether women in pregnancy and the postpartum year can complete a structured course of TMS, whether they find it acceptable, and whether safety signals remain manageable across maternal and infant follow-up.
If adherence is high and adverse events remain acceptable, the protocol could justify a controlled trial with a comparator arm and longer follow-up. If completion proves difficult or obstetric concerns emerge, the field will have a clearer sense of the barriers that need to be addressed before TMS can move toward broader perinatal use.